| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Pamela U Freda, Laurence Katznelson, Aart Jan van der Lely, Carlos M Reyes, Shouhao Zhao, Daniel Rabinowit. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. The Journal of clinical endocrinology and metabolism. vol 90. issue 8. 2005-09-14. PMID:15886238. |
long-acting somatostatin analog therapy of acromegaly: a meta-analysis. |
2005-09-14 |
2023-08-12 |
Not clear |
| Pamela U Freda, Laurence Katznelson, Aart Jan van der Lely, Carlos M Reyes, Shouhao Zhao, Daniel Rabinowit. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. The Journal of clinical endocrinology and metabolism. vol 90. issue 8. 2005-09-14. PMID:15886238. |
although considerable data exist on the use of long-acting somatostatin analogs to treat acromegaly, their reported efficacy differs substantially among trials. |
2005-09-14 |
2023-08-12 |
Not clear |
| M Filopanti, C Ronchi, E Ballarè, S Bondioni, A G Lania, M Losa, S Gelmini, A Peri, C Orlando, P Beck-Peccoz, A Spad. Analysis of somatostatin receptors 2 and 5 polymorphisms in patients with acromegaly. The Journal of clinical endocrinology and metabolism. vol 90. issue 8. 2005-09-14. PMID:15914528. |
analysis of somatostatin receptors 2 and 5 polymorphisms in patients with acromegaly. |
2005-09-14 |
2023-08-12 |
Not clear |
| U Plöckinger, H-J Quabb. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study. Acta neurochirurgica. vol 147. issue 5. 2005-08-18. PMID:15806331. |
the effect of presurgical long-acting somatostatin analogue (ssa) treatment on operative outcome in acromegaly is as yet uncertain and long-term observations are lacking. |
2005-08-18 |
2023-08-12 |
Not clear |
| Peiming Ma, Yanfeng Wang, Joost van der Hoek, Jerry Nedelman, Horst Schran, Ly-Le Tran, Steven W J Lambert. Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly. Clinical pharmacology and therapeutics. vol 78. issue 1. 2005-08-18. PMID:16003295. |
pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, som230, with octreotide in patients with acromegaly. |
2005-08-18 |
2023-08-12 |
Not clear |
| J A Gilbert, J P Miell, S M Chambers, A M McGregor, S J B Aylwi. The nadir growth hormone after an octreotide test dose predicts the long-term efficacy of somatostatin analogue therapy in acromegaly. Clinical endocrinology. vol 62. issue 6. 2005-08-11. PMID:15943838. |
the nadir growth hormone after an octreotide test dose predicts the long-term efficacy of somatostatin analogue therapy in acromegaly. |
2005-08-11 |
2023-08-12 |
Not clear |
| J A Gilbert, J P Miell, S M Chambers, A M McGregor, S J B Aylwi. The nadir growth hormone after an octreotide test dose predicts the long-term efficacy of somatostatin analogue therapy in acromegaly. Clinical endocrinology. vol 62. issue 6. 2005-08-11. PMID:15943838. |
in the treatment of acromegaly, a 'test dose' of octreotide is recommended prior to the use of depot somatostatin analogue (ssa) therapy. |
2005-08-11 |
2023-08-12 |
Not clear |
| Shlomo Melmed, Richard Sternberg, David Cook, Anne Klibanski, Philippe Chanson, Vivien Bonert, Mary Lee Vance, David Rhew, David Kleinberg, Ariel Barka. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. The Journal of clinical endocrinology and metabolism. vol 90. issue 7. 2005-08-09. PMID:15827109. |
the results of studies evaluating acromegaly treatment with the somatostatin receptor ligands (srls), octreotide and lanreotide, have supported the use of these agents for primary medical therapy before or as an alternative to traditional interventions of surgery and radiotherapy in selected cases. |
2005-08-09 |
2023-08-12 |
Not clear |
| David L Kleinber. Primary therapy for acromegaly with somatostatin analogs and a discussion of novel peptide analogs. Reviews in endocrine & metabolic disorders. vol 6. issue 1. 2005-07-08. PMID:15711912. |
primary therapy for acromegaly with somatostatin analogs and a discussion of novel peptide analogs. |
2005-07-08 |
2023-08-12 |
Not clear |
| John Was. Debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogues. European journal of endocrinology. vol 152. issue 5. 2005-06-28. PMID:15879353. |
debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogues. |
2005-06-28 |
2023-08-12 |
Not clear |
| Carlo Cappelli, Elena Gandossi, Barbara Agosti, Bruno Cerudelli, Davide Cumetti, Maurizio Castellano, Ilenia Pirola, Elvira De Martino, Enrico Agabiti Rose. Long-term treatment of acromegaly with lanreotide: evidence of increased serum parathormone concentration. Endocrine journal. vol 51. issue 6. 2005-06-16. PMID:15644568. |
the somatostatin analogue lanreotide is effective in reducing growth hormone levels in patients with acromegaly. |
2005-06-16 |
2023-08-12 |
Not clear |
| Niki Karavitaki, Ileana Botusan, Serban Radian, Mihail Coculescu, Helen E Turner, John A H Was. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly. Clinical endocrinology. vol 62. issue 3. 2005-06-16. PMID:15730408. |
the value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly. |
2005-06-16 |
2023-08-12 |
Not clear |
| Niki Karavitaki, Ileana Botusan, Serban Radian, Mihail Coculescu, Helen E Turner, John A H Was. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly. Clinical endocrinology. vol 62. issue 3. 2005-06-16. PMID:15730408. |
the long-acting depot somatostatin analogues [octreotide lar (lar) and lanreotide (lan)] are among the most effective available medical therapies for acromegaly. |
2005-06-16 |
2023-08-12 |
Not clear |
| J Feenstra, W W de Herder, S M T H ten Have, A W van den Beld, R A Feelders, J A M J L Janssen, A J van der Lel. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet (London, England). vol 365. issue 9471. 2005-05-24. PMID:15885297. |
combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. |
2005-05-24 |
2023-08-12 |
Not clear |
| J Feenstra, W W de Herder, S M T H ten Have, A W van den Beld, R A Feelders, J A M J L Janssen, A J van der Lel. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet (London, England). vol 365. issue 9471. 2005-05-24. PMID:15885297. |
in a 42-week dose-finding study, we assessed the efficacy of the combination of long-acting somatostatin analogues once monthly and pegvisomant once weekly in 26 patients with active acromegaly. |
2005-05-24 |
2023-08-12 |
Not clear |
| Dinesh Selvarajah, Jonathan Webster, Richard Ross, John Newell-Pric. Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly. European journal of endocrinology. vol 152. issue 4. 2005-05-19. PMID:15817912. |
effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly. |
2005-05-19 |
2023-08-12 |
human |
| Ryszard Waśko, Paweł Bolko, Maciej Owecki, Magdalena Jaskuła, Jerzy Sowińsk. The efficacy of octreotide LAR (long acting release) treatment in patients with somatotropinoma, and mixed pituitary tumours. Pharmacy world & science : PWS. vol 26. issue 6. 2005-04-21. PMID:15683101. |
the efficacy of somatostatin analogues in the treatment of acromegaly is not always equal and therefore we wanted to evaluate the efficacy of therapy with octreotide long acting release (lar) in patients with monohormonal tumours (somatotropinomas) in comparison to individuals with mixed pituitary tumours secreting alpha-subunit. |
2005-04-21 |
2023-08-12 |
Not clear |
| John J Gilroy, R Andrew Jame. Optimizing somatostatin analog therapy in acromegaly: long-acting formulations. Treatments in endocrinology. vol 1. issue 3. 2005-04-19. PMID:15799207. |
optimizing somatostatin analog therapy in acromegaly: long-acting formulations. |
2005-04-19 |
2023-08-12 |
Not clear |
| John J Gilroy, R Andrew Jame. Optimizing somatostatin analog therapy in acromegaly: long-acting formulations. Treatments in endocrinology. vol 1. issue 3. 2005-04-19. PMID:15799207. |
somatostatin peptide analogs have revolutionized the medical treatment of patients with acromegaly. |
2005-04-19 |
2023-08-12 |
Not clear |
| John S Beva. Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly. The Journal of clinical endocrinology and metabolism. vol 90. issue 3. 2005-04-12. PMID:15613435. |
clinical review: the antitumoral effects of somatostatin analog therapy in acromegaly. |
2005-04-12 |
2023-08-12 |
Not clear |